RMR Wealth Builders Sells 53 Shares of Humana Inc. (NYSE:HUM)

RMR Wealth Builders decreased its position in Humana Inc. (NYSE:HUM) by 2.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,023 shares of the insurance provider’s stock after selling 53 shares during the period. RMR Wealth Builders’ holdings in Humana were worth $513,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of HUM. Park Avenue Securities LLC increased its stake in shares of Humana by 77.8% during the fourth quarter. Park Avenue Securities LLC now owns 8,635 shares of the insurance provider’s stock valued at $2,191,000 after buying an additional 3,778 shares during the period. Assenagon Asset Management S.A. increased its position in Humana by 21.5% during the 4th quarter. Assenagon Asset Management S.A. now owns 4,969 shares of the insurance provider’s stock valued at $1,261,000 after purchasing an additional 879 shares during the period. 180 Wealth Advisors LLC raised its holdings in shares of Humana by 15.6% in the 4th quarter. 180 Wealth Advisors LLC now owns 1,291 shares of the insurance provider’s stock valued at $327,000 after purchasing an additional 174 shares in the last quarter. FNY Investment Advisers LLC lifted its position in shares of Humana by 6,647.5% in the 4th quarter. FNY Investment Advisers LLC now owns 27,260 shares of the insurance provider’s stock worth $6,916,000 after purchasing an additional 26,856 shares during the period. Finally, Future Financial Wealth Managment LLC raised its stake in Humana by 20.0% in the fourth quarter. Future Financial Wealth Managment LLC now owns 600 shares of the insurance provider’s stock worth $152,000 after buying an additional 100 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Insider Activity

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.29% of the company’s stock.

Humana Trading Down 0.9 %

Shares of Humana stock opened at $280.20 on Thursday. The business’s fifty day moving average is $274.33 and its two-hundred day moving average is $309.10. Humana Inc. has a fifty-two week low of $213.31 and a fifty-two week high of $455.53. The firm has a market cap of $33.74 billion, a PE ratio of 24.82, a P/E/G ratio of 2.02 and a beta of 0.55. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.67.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. The company had revenue of $29.30 billion for the quarter, compared to the consensus estimate of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. Analysts anticipate that Humana Inc. will post 16.14 earnings per share for the current year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.26%. The ex-dividend date is Tuesday, December 31st. Humana’s payout ratio is currently 31.36%.

Wall Street Analysts Forecast Growth

HUM has been the subject of a number of analyst reports. Bank of America upgraded Humana from an “underperform” rating to a “neutral” rating and upped their price objective for the stock from $247.00 to $308.00 in a research note on Wednesday, November 6th. Cantor Fitzgerald restated a “neutral” rating and issued a $395.00 price target on shares of Humana in a report on Tuesday, October 1st. Jefferies Financial Group lowered shares of Humana from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $519.00 to $253.00 in a research note on Monday, October 7th. Wells Fargo & Company lowered their price target on Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Finally, Deutsche Bank Aktiengesellschaft lowered their target price on Humana from $349.00 to $250.00 and set a “hold” rating on the stock in a research note on Thursday, October 3rd. Twenty investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $302.70.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.